USE OF AN INDIRECT PHARMACODYNAMIC STIMULATION MODEL OF MX PROTEIN INDUCTION TO COMPARE IN-VIVO ACTIVITY OF INTERFERON ALFA-2A AND A POLYETHYLENE GLYCOL-MODIFIED DERIVATIVE IN HEALTHY-SUBJECTS

Citation
Ka. Nieforth et al., USE OF AN INDIRECT PHARMACODYNAMIC STIMULATION MODEL OF MX PROTEIN INDUCTION TO COMPARE IN-VIVO ACTIVITY OF INTERFERON ALFA-2A AND A POLYETHYLENE GLYCOL-MODIFIED DERIVATIVE IN HEALTHY-SUBJECTS, Clinical pharmacology and therapeutics, 59(6), 1996, pp. 636-646
Citations number
27
Categorie Soggetti
Pharmacology & Pharmacy
ISSN journal
00099236
Volume
59
Issue
6
Year of publication
1996
Pages
636 - 646
Database
ISI
SICI code
0009-9236(1996)59:6<636:UOAIPS>2.0.ZU;2-K
Abstract
Interferon alfa-2a was chemically modified by the covalent attachment of a polyethylene glycol (PEG) moiety to enhance its circulating half- life and to reduce its immunogenicity. A comparative evaluation of the pharmacokinetics of the PEG-modified interferon alfa-2a showed a grea ter than twofold increase in the circulating half-life as a result of this chemical modification, An indirect physiologic response model was developed to characterize the time course of the MX protein response after subcutaneous administration of single ascending doses of either interferon alfa-2a or PEG-interferon alfa-2a in healthy volunteers. An alysis of the pharmacokinetic-pharmacodynamic relationship suggested t hat the PEG-modified interferon alfa-2a could not be administered less than twice weekly and therefore offered little therapeutic advantage over its unmodified counterpart, which is administered three times wee kly. These results were consistent with findings in phase TI trials, T his study substantiates the usefulness of pharmacodynamic modeling as a tool for the development of dose recommendations and for the early s election of drug candidates in the drug development process.